Европейская академия естественных наук Hannover E.V.

Huang Wenlin

Prof. Huang Wenlin, a distinguished Professor of the Cancer Center Sun Yat-sen University (second-level), and Chairman of Guangzhou Doublle Bioproducts Co., Ltd. He is recognized as a national key talent, hounered special government allowances from the State Council.

In the academic field，Professor Huang has led several major research projects in China, overs 180+ SCI papers published in cutting edge journals, including "Nature Medicine." His profound expertise focuses in the fields of gene therapy and cell therapy.

Under his leadership, the team successfully translated laboratory research into tangible outcomes by commercializing with five innovative products in gene therapy and immunotherapy. Notably, the recombinant human endostation adenovirus injection became the first gene therapy drug to complete Phase III clinical trials in China. His pioneering efforts facilitated the successful transformation of these innovative solutions into practical products demanded by the market.

As an educator, Professor Huang has spearheaded the creation of various academic works and graduate textbooks, laying a solid foundation for cultivating the next generation of biomedical professionals in China. His contributions have earned him national-level awards, including the National Science and Technology Progress Award (Second Prize) and the National Patent Gold Award, significantly contributing to the advancement of the academic field.

Dedicated to fostering international collaboration, Professor Huang actively engages in cross-border cooperation, aiming to share advanced knowledge and drive the internationalization of research outcomes. His commitment extends towards providing more advanced and effective treatment solutions for global patients, injecting new vitality into the technological innovation and industrial application within the field of biomedicine. His personal contributions have not only deeply impacted the academic sphere but have also set a benchmark in the industry, contributing to technological innovation and the development of the biopharmaceutical sector.

 

вверх

Энциклопедия ЕАЕН

 ¦  Impressum  ¦  Контакт